What is Silo Pharma Inc's earnings per share (EPS)?

Silo Pharma Inc (SILO) reported diluted earnings per share of -$0.50 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Silo Pharma Inc Financials

SILO

FY2025 annual

Revenue $72K 0.0% YoY

Net Income -$4.2M +3.8% YoY

EPS (Diluted) -$0.50 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Silo Pharma Inc (SILO) reported $72K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SILO FY2025 2026-08-15

Development-stage economics dominate: operating costs exceed commercial revenue, while external financing replenishes cash.

Cash increased to $4.7M in FY2025 even as operating cash flow deteriorated to -$4.7M, because financing supplied $4.9M; the balance-sheet improvement therefore came from funding activity rather than internal cash generation. That pattern also makes the 11.4x current ratio more a liquidity snapshot than evidence of a self-financing operating model.

At $72K of revenue, research and development consumed $2.2M, nearly thirty times reported sales, confirming that the business is still funding development ahead of meaningful commercial scale. The operating loss remained about $4.3M, so R&D is only one part of the cost structure.

Gross margin fell from 91.9% in FY2024 to 38.6% in FY2025 as cost of revenue rose to $44K; despite that mix or cost shift, the operating loss narrowed from $4.7M to $4.3M, helped by lower R&D. Liabilities also declined to $1.3M, leaving cash well above near-term obligations but not eliminating the need for continued funding while operating cash flow stays negative.

Financial Health Signals

Financial health score not available

Silo Pharma Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.32

Silo Pharma Inc scores -2.32, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.5M) relative to total liabilities ($1.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Silo Pharma Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Silo Pharma Inc reported a net loss of $4.2M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Silo Pharma Inc reported an operating loss of $4.3M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$72K

YoY0.0%

5Y CAGR+12.0%

Silo Pharma Inc generated $72K in revenue in fiscal year 2025. That is unchanged from the prior year.

Net Income

-$4.2M

YoY+3.8%

Silo Pharma Inc reported -$4.2M in net income in fiscal year 2025. This represents an increase of 3.8% from the prior year.

EPS (Diluted)

-$0.50

Silo Pharma Inc earned -$0.50 per diluted share (EPS) in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$4.7M

YoY+21.6%

5Y CAGR+33.3%

10Y CAGR+164.9%

Silo Pharma Inc held $4.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

14M

Silo Pharma Inc had 14M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

38.6%

YoY-53.3pp

Silo Pharma Inc's gross margin was 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.3 percentage points from the prior year.

Return on Equity

-67.0%

YoY+20.2pp

5Y CAGR+170.1pp

Silo Pharma Inc's ROE was -67.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.2 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$2.2M

YoY-8.8%

5Y CAGR+141.6%

Silo Pharma Inc invested $2.2M in research and development in fiscal year 2025. This represents a decrease of 8.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

SILO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SILO quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY13	FY12	FY11
Revenue	N/A	$72K0.0%	$72K0.0%	$72K0.0%	$72K+5858.8%	$1K-97.0%	$41K+0.9%	$41K	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	$44K+658.7%	$6K0.0%	$6K0.0%	$6K+16.7%	$5K-97.2%	$176K+543.1%	$27K	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$28K-58.0%	$66K0.0%	$66K0.0%	$66K+1846.5%	-$4K+97.2%	-$135K-1125.7%	$13K	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.2M	$2.2M-8.8%	$2.4M+180.2%	$845K-34.3%	$1.3M+85.4%	$694K+2543.5%	$26K	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	$390K+71.6%	$227K+39.5%	$163K+224.7%	$50K-42.3%	$87K+14.4%	$76K+157.3%	$30K	$10K	N/A	N/A
Operating Income	-$4.5M	-$4.3M+9.0%	-$4.7M-22.0%	-$3.9M-6.3%	-$3.6M-32.2%	-$2.7M-24.6%	-$2.2M-136.6%	-$930K-56.6%	-$594K-21.1%	-$491K	N/A	N/A	N/A
Interest Expense	$40K	$37K+633.7%	$5K+4.4%	$5K+121.4%	$2K-27.6%	$3K+3695.0%	$80	$0	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$25K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M	-$4.2M+3.8%	-$4.4M-18.7%	-$3.7M+5.3%	-$3.9M-200.1%	$3.9M+228.5%	-$3.0M-199.8%	-$1.0M-4.5%	-$969K-371.9%	$357K	N/A	N/A	N/A
EPS (Diluted)	—	-$0.50	-$1.19+0.8%	-$1.20+29.8%	-$1.71	$0.04	-$0.05	N/A	-$0.02	$0.01	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K
Cost of Revenue	N/A	$21K0.0%	$21K0.0%	$21K+1317.9%	$1K-0.1%	$1K0.0%	$1K+0.1%	$1K
Gross Profit	N/A	-$3K0.0%	-$3K0.0%	-$3K-116.1%	$17K0.0%	$17K0.0%	$17K0.0%	$17K
R&D Expenses	$298K-70.5%	$1.0M+231.1%	$306K-43.7%	$544K-24.2%	$717K+20.8%	$594K-47.9%	$1.1M+120.2%	$518K
Operating Income	-$929K+41.7%	-$1.6M-102.7%	-$787K+31.7%	-$1.2M+7.8%	-$1.2M-14.1%	-$1.1M+39.7%	-$1.8M-79.5%	-$1.0M
Interest Expense	$3K-15.1%	$3K-89.7%	$33K+3591.0%	$886-46.2%	$2K-20.2%	$2K+654.0%	$274-74.7%	$1K
Net Income	-$833K+49.4%	-$1.6M-86.8%	-$882K+20.6%	-$1.1M+7.8%	-$1.2M-16.8%	-$1.0M+40.4%	-$1.7M-86.3%	-$929K
EPS (Diluted)	-$0.76	-$0.12	$0.00+100.0%	-$0.12	-$2.88	-$0.23+43.9%	-$0.41-86.4%	-$0.22

Not reported in any period shown, so not listed: SG&A Expenses, Income Tax.

SILO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SILO quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY13	FY12	FY11
Total Assets	$7.6M+2.6%	$7.4M-4.3%	$7.7M-33.5%	$11.6M+11.0%	$10.5M+635.3%	$1.4M+188.9%	$494K-42.3%	$855K-47.9%	$1.6M	$2.2M+791077.1%	$279-84.1%	$2K
Current Assets	$7.4M+3.9%	$7.1M-7.4%	$7.7M-33.6%	$11.6M+11.2%	$10.4M+629.1%	$1.4M+188.9%	$494K-21.1%	$626K-61.9%	$1.6M	N/A	$279-84.1%	$2K
Cash & Equivalents	$4.7M+21.6%	$3.9M+10.8%	$3.5M-69.0%	$11.4M+15.6%	$9.8M+771.8%	$1.1M+909.7%	$112K-66.8%	$337K+14.3%	$295K	$2.0M+720552.3%	$279-84.1%	$2K
Inventory	N/A	N/A	N/A	N/A	N/A	$33K-78.6%	$156K+479.7%	$27K	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-45.3%	$2.4M+51.5%	$1.6M+20.5%	$1.3M-8.8%	$1.4M+878.2%	$146K-71.8%	$517K+15.3%	$448K+2.2%	$438K	$19K-54.9%	$41K+1084.9%	$4K
Current Liabilities	$650K-60.7%	$1.7M+113.5%	$776K+77.8%	$436K-11.0%	$490K+245.8%	$142K+21.4%	$117K+143.3%	$48K+25.1%	$38K	N/A	$26K+634.0%	$4K
Total Equity	$6.3M+25.3%	$5.0M-18.5%	$6.2M-40.3%	$10.3M+14.1%	$9.1M+607.6%	$1.3M+5694.5%	-$23K-105.6%	$407K-66.1%	$1.2M	$1.8M+4442.1%	-$41K-2256.6%	-$2K
Retained Earnings	-$19.5M-27.7%	-$15.3M-40.4%	-$10.9M-51.6%	-$7.2M-119.8%	-$3.3M+43.4%	-$5.8M-117.0%	-$2.7M-61.7%	-$1.6M	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$6.0M-15.2%	$7.0M-7.7%	$7.6M+19.1%	$6.4M-4.0%	$6.7M+12.8%	$5.9M-20.4%	$7.4M-13.5%	$8.6M
Current Assets	$5.7M-16.0%	$6.8M-7.9%	$7.4M+19.8%	$6.2M-3.3%	$6.4M+13.7%	$5.6M-21.2%	$7.1M-13.9%	$8.3M
Cash & Equivalents	$3.3M-16.0%	$3.9M-17.8%	$4.7M+21.2%	$3.9M-9.6%	$4.3M+38.2%	$3.1M-19.7%	$3.9M-19.6%	$4.9M
Total Liabilities	$1.1M-20.2%	$1.3M+2.8%	$1.3M-5.5%	$1.4M-20.7%	$1.7M-8.1%	$1.9M-20.6%	$2.4M+33.2%	$1.8M
Current Liabilities	$1.1M+51.2%	$705K+8.4%	$650K-8.2%	$708K-32.5%	$1.0M-11.4%	$1.2M-28.4%	$1.7M+58.5%	$1.0M
Total Equity	$4.9M-14.0%	$5.7M-9.9%	$6.3M+25.9%	$5.0M+1.9%	$4.9M+22.6%	$4.0M-20.3%	$5.0M-25.8%	$6.8M
Retained Earnings	-$22.0M-3.9%	-$21.1M-8.5%	-$19.5M-4.7%	-$18.6M-6.3%	-$17.5M-7.4%	-$16.3M-6.8%	-$15.3M-12.8%	-$13.5M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

SILO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SILO quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY13	FY12	FY11
Operating Cash Flow	-$3.3M	-$4.7M-21.6%	-$3.8M-18.9%	-$3.2M+7.8%	-$3.5M-53.5%	-$2.3M-96.9%	-$1.2M-45.7%	-$794K-391.3%	$273K+195.8%	-$285K	-$182K	N/A	N/A
Investing Cash Flow	-$456K	$644K-33.9%	$974K+123.5%	-$4.1M-4882.9%	$87K-98.8%	$7.2M+18342.4%	$39K-79.1%	$187K+174.7%	-$250K	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$4.9M+49.9%	$3.2M+788.1%	-$471K-109.5%	$4.9M+30.2%	$3.8M+77.7%	$2.1M+457.8%	$383K+1867.3%	$19K	N/A	$2.2M	N/A	$575

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$782K+5.0%	-$823K-5.4%	-$780K+18.3%	-$955K+25.7%	-$1.3M+21.6%	-$1.6M-78.8%	-$917K+31.9%	-$1.3M
Investing Cash Flow	$183K+878.5%	-$24K+95.5%	-$520K-444.6%	-$95K-124.6%	$388K-55.5%	$871K+2413.9%	-$38K+6.9%	-$40K
Financing Cash Flow	N/A	N/A	$2.1M+235.7%	$635K	N/A	N/A	$0-100.0%	$1.7M

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

SILO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

SILO quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY13	FY12	FY11
Gross Margin	38.6%-53.3pp	91.9%0.0pp	91.9%0.0pp	91.9%	-313.6%	-330.4%	32.5%	N/A	N/A	N/A	N/A	N/A
Operating Margin	-5936.9%	-6526.4%	-5347.4%	-5031.3%	-226805.2%	-5380.1%	-2293.4%	N/A	N/A	N/A	N/A	N/A
Net Margin	-5863.5%	-6092.6%	-5132.6%	-5420.9%	322623.2%	-7422.5%	-2497.7%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-67.0%+20.2pp	-87.3%-27.4pp	-59.9%-22.1pp	-37.8%-80.9pp	43.1%+280.3pp	-237.2%	N/A	-237.9%-267.6pp	29.6%	N/A	N/A	N/A
Return on Assets	-55.6%+3.7pp	-59.3%-11.5pp	-47.8%-14.2pp	-33.6%-70.8pp	37.2%+250.1pp	-212.9%-7.7pp	-205.2%-91.9pp	-113.3%-135.1pp	21.7%	N/A	N/A	N/A
Current Ratio	11.36+7.1x	4.29-5.6x	9.90-16.6x	26.52+5.3x	21.23+11.2x	10.07+5.8x	4.23-8.8x	13.05-29.8x	42.81	N/A	0.01-0.5x	0.50
Debt-to-Equity	0.21-0.3x	0.47+0.2x	0.25+0.1x	0.130.0x	0.160.0x	0.11	N/A	1.10+0.7x	0.36	0.01	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	-14.8%0.0pp	-14.8%0.0pp	-14.8%-106.7pp	91.9%0.0pp	91.9%0.0pp	91.9%0.0pp	91.9%
Operating Margin	N/A	-8846.4%	-4363.3%	-6388.2%	-6926.8%	-6069.7%	-10059.7%	-5603.6%
Net Margin	N/A	-9137.4%	-4890.3%	-6160.5%	-6681.2%	-5721.9%	-9600.7%	-5152.9%
Return on Equity	-17.0%+11.9pp	-29.0%-15.0pp	-14.0%+8.2pp	-22.2%+2.3pp	-24.5%+1.2pp	-25.7%+8.7pp	-34.4%-20.7pp	-13.7%
Return on Assets	-14.0%+9.5pp	-23.5%-11.9pp	-11.6%+5.8pp	-17.4%+0.7pp	-18.1%-0.6pp	-17.5%+5.9pp	-23.4%-12.5pp	-10.8%
Current Ratio	5.36-4.3x	9.65-1.7x	11.36+2.7x	8.70+2.6x	6.07+1.3x	4.73+0.4x	4.29-3.6x	7.91
Debt-to-Equity	0.220.0x	0.240.0x	0.21-0.1x	0.27-0.1x	0.35-0.1x	0.470.0x	0.47+0.2x	0.26

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Artelo Biosciences Inc ARTL

$3.0M

Pharmacyte Biotech Inc PMCB

$5.8M

CERo Therapeutics CERO

$177K

Ensysce Biosciences Inc ENSC

$7.8M

Polyrizon Ltd PLRZ

$26.7M

Where Silo Pharma Inc Ranks

Frequently Asked Questions

What is Silo Pharma Inc's annual revenue?

Silo Pharma Inc (SILO) reported $72K in total revenue for fiscal year 2025. That is unchanged from the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Silo Pharma Inc's revenue growing?

Silo Pharma Inc (SILO) revenue was essentially unchanged year-over-year, at $72K in fiscal year 2025 against $72K the year before.

Is Silo Pharma Inc profitable?

No, Silo Pharma Inc (SILO) reported a net income of -$4.2M in fiscal year 2025.

What is Silo Pharma Inc's gross margin?

Silo Pharma Inc (SILO) had a gross margin of 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Silo Pharma Inc's return on equity (ROE)?

Silo Pharma Inc (SILO) has a return on equity of -67.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Silo Pharma Inc's operating cash flow?

Silo Pharma Inc (SILO) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Silo Pharma Inc's total assets?

Silo Pharma Inc (SILO) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Silo Pharma Inc spend on research and development?

Silo Pharma Inc (SILO) invested $2.2M in research and development during fiscal year 2025.

How many shares does Silo Pharma Inc have outstanding?

Silo Pharma Inc (SILO) had 14M shares outstanding as of fiscal year 2025.

What is Silo Pharma Inc's current ratio?

Silo Pharma Inc (SILO) had a current ratio of 11.36 as of fiscal year 2025, which is generally considered healthy.

What is Silo Pharma Inc's debt-to-equity ratio?

Silo Pharma Inc (SILO) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Silo Pharma Inc's return on assets (ROA)?

Silo Pharma Inc (SILO) had a return on assets of -55.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Silo Pharma Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Silo Pharma Inc (SILO) held $6.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Silo Pharma Inc's Altman Z-Score?

Silo Pharma Inc (SILO) has an Altman Z-Score of -2.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Silo Pharma Inc's Piotroski F-Score?

Silo Pharma Inc (SILO) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Silo Pharma Inc's earnings high quality?

Silo Pharma Inc (SILO) reported a net loss of $4.2M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Silo Pharma Inc cover its interest payments?

Silo Pharma Inc (SILO) reported an operating loss of $4.3M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.